Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | EGLN1 | Q9GZT9 | 7/20 | 0.44 |
| ▸ | APLNR | P35414 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5768267 | 0.91 | HSD17B10 (0.43) | KDM4ETSHRGRM5 | |
| SCHEMBL4146440 | 0.89 | KDM4E (0.45) | KDM4EMAPK1EGLN1ALDH1A1TSHR | |
| SCHEMBL14573839 | 0.86 | KDM4E (0.42) | KDM4EMAPK1EGLN1ALDH1A1TSHR | |
| SCHEMBL5768580 | 0.84 | MEN1 (0.55) | KDM4EALDH1A1TSHRMAPT | |
| SCHEMBL6100789 | 0.81 | CMA1 (0.53) | KDM4EMAPK1ALDH1A1MAPT | |
| SCHEMBL5770231 | 0.79 | GAA (0.44) | KDM4EALDH1A1TSHRSMN1; SMN2MAPT | |
| SCHEMBL12378291 | 0.78 | EGLN1 (0.41) | KDM4EEGLN1SMN1; SMN2 | |
| SCHEMBL5766283 | 0.78 | MEN1 (0.39) | KDM4EMAPK1ALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL19577090 | 0.76 | APLNR (0.54) | KDM4EMAPK1APLNRALDH1A1TSHR | |
| SCHEMBL382858 | 0.76 | KDM4E (0.51) | KDM4EMAPK1ALDH1A1GRM5SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060211724-A1 | Hiv integrase inhibitors | VERSCHUEREN GASTON W | 2006-09-21 | — | — | US | disclosed |
| EP-1625130-A2 | HIV INTEGRASE INHIBITORS | Tibotec Pharmaceuticals Ltd. (IE) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004096807-A2 | HIV INTEGRASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211724-A1 | Hiv integrase inhibitors | SULT1A1, SULT2A1, SULT1E1 | KDM4E 4133/4885MAPK1 1746/4885EGLN1 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.